Bradley J Kendall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5492694/publications.pdf

Version: 2024-02-01

304743 265206 52 1,852 22 42 citations h-index g-index papers 52 52 52 2261 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. Gut, 2022, 71, 1053-1061.	12.1	74
2	Demographic and lifestyle risk factors for gastroesophageal reflux disease and Barrett's esophagus in Australia. Ecological Management and Restoration, 2022, 35, .	0.4	9
3	Mechanisms for the Sex-Specific Effect of (i>H. Pylori (li>on Risk of Gastroesophageal Reflux Disease and Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1630-1637.	2.5	2
4	Improving the Quality of Bowel Preparation: Rewarding Patients for Success or Intensive Patient Education?. Digestive Diseases, 2021, 39, 113-118.	1.9	5
5	Epigastric symptom response to low FODMAP dietary advice compared with standard dietetic advice in individuals with functional dyspepsia. Neurogastroenterology and Motility, 2021, 33, e14148.	3.0	16
6	Development of EndoScreen Chip, a Microfluidic Pre-Endoscopy Triage Test for Esophageal Adenocarcinoma. Cancers, 2021, 13, 2865.	3.7	4
7	Colorectal cancer Outcomes in people with Severe Mental Illness Cohort (COSMIC): a protocol for an Australian retrospective cohort using linked administrative data. BMJ Open, 2021, 11, e044737.	1.9	3
8	Assessing the genetic relationship between gastro-esophageal reflux disease and risk of COVID-19 infection. Human Molecular Genetics, 2021, , .	2.9	7
9	Diet and risk of gastro-oesophageal reflux disease in the Melbourne Collaborative Cohort Study. Public Health Nutrition, 2021, 24, 5034-5046.	2.2	8
10	An Evidence-based Approach Towards Targeted Patient Education to Improve Bowel Preparation for Colonoscopy. Journal of Clinical Gastroenterology, 2020, 54, 707-713.	2.2	6
11	Sex Differences in the Risk of Barrett's Esophagus Associated With the Metabolic Effects of Obesity. Journal of Clinical Gastroenterology, 2020, 54, 795-800.	2.2	6
12	Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008–2016. Ecological Management and Restoration, 2020, 34, .	0.4	0
13	Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 155-167.	3.7	28
14	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. American Journal of Gastroenterology, 2020, 115, 190-201.	0.4	102
15	Colorectal, cervical and prostate cancer screening in Australians with severe mental illness: Retrospective nation-wide cohort study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 550-558.	2.3	21
16	The impact of reducing alcohol consumption in Australia: An estimate of the proportion of potentially avoidable cancers 2013–2037. International Journal of Cancer, 2019, 145, 2944-2953.	5.1	8
17	The impact of changing the prevalence of overweight/obesity and physical inactivity in Australia: An estimate of the proportion of potentially avoidable cancers 2013–2037. International Journal of Cancer, 2019, 144, 2088-2098.	5.1	20
18	Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Digestive Diseases and Sciences, 2019, 64, 480-486.	2.3	102

#	Article	IF	CITATIONS
19	Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and GeneticÂVariants. Gastroenterology, 2018, 154, 1273-1281.e3.	1.3	67
20	Influence of Simethicone Added to the Rinse Water during Colonoscopies on Polyp Detection Rates: Results of an Unintended Cohort Study. Digestion, 2018, 98, 217-221.	2.3	14
21	How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. International Journal of Cancer, 2018, 142, 691-701.	5.1	71
22	Barrett's oesophagus: epidemiology, diagnosis and clinical management. Medical Journal of Australia, 2016, 205, 317-324.	1.7	18
23	Liverâ€related mortality in countries of the developed world: an ecological study approach to explain the variability. Alimentary Pharmacology and Therapeutics, 2016, 44, 68-77.	3.7	9
24	Accuracy of polyp localization at colonoscopy. Endoscopy International Open, 2016, 04, E642-E646.	1.8	9
25	Inverse Association Between Gluteofemoral Obesity and Risk ofÂBarrett's Esophagus in a Pooled Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1412-1419.e3.	4.4	12
26	Obesity in Relation to Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Current Nutrition Reports, 2016, 5, 41-47.	4.3	0
27	Cancers prevented in Australia in 2010 through the consumption of aspirin. Australian and New Zealand Journal of Public Health, 2015, 39, 414-417.	1.8	8
28	Cancers in Australia in 2010 attributable to infectious agents. Australian and New Zealand Journal of Public Health, 2015, 39, 446-451.	1.8	30
29	Cancers in Australia in 2010 attributable to overweight and obesity. Australian and New Zealand Journal of Public Health, 2015, 39, 452-457.	1.8	36
30	Cancers in Australia in 2010 attributable to modifiable factors: introduction and overview. Australian and New Zealand Journal of Public Health, 2015, 39, 403-407.	1.8	35
31	Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions. Australian and New Zealand Journal of Public Health, 2015, 39, 477-484.	1.8	93
32	Symptoms of Obstructive Sleep Apnea, Gastroesophageal Reflux and the Risk of Barrett's Esophagus in a Population-Based Case-Control Study. PLoS ONE, 2015, 10, e0129836.	2.5	16
33	Cancers in Australia in 2010 attributable to insufficient physical activity. Australian and New Zealand Journal of Public Health, 2015, 39, 458-463.	1.8	21
34	Australian clinical practice guidelines for the diagnosis and management of <scp>B</scp> arrett's esophagus and early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 804-820.	2.8	104
35	Unravelling the Riddle of Gastroesophageal Reflux Disease, Obesity, and Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 2273-2275.	4.4	13
36	Total body fat and the risk of Barrett's oesophagus – A bioelectrical impedance study. Cancer Epidemiology, 2014, 38, 266-272.	1.9	14

#	Article	IF	CITATIONS
37	A Model to Determine Absolute Risk for Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2013, 11, 138-144.e2.	4.4	68
38	The risk of Barrett's esophagus associated with abdominal obesity in males and females. International Journal of Cancer, 2013, 132, 2192-2199.	5.1	37
39	A Clinical Risk Prediction Model for Barrett Esophagus. Cancer Prevention Research, 2012, 5, 1115-1123.	1.5	67
40	Letters to the Editor. American Journal of Gastroenterology, 2007, 102, 201-221.	0.4	19
41	Leptin and the risk of Barrett's oesophagus. Gut, 2007, 57, 448-454.	12.1	126
42	Temporal Changes in the Endoscopic Frequency of New Cases of Barrett's Esophagus in an Australian Health Region. American Journal of Gastroenterology, 2006, 101, 1178-1182.	0.4	46
43	Postoperative ERCP Versus Laparoscopic Choledochotomy for Clearance of Selected Bile Duct Calculi. Annals of Surgery, 2005, 242, 188-192.	4.2	205
44	Cisapride in the Long-Term Treatment of Chronic Gastroparesis: A 2-Year Open-Label Study. Journal of International Medical Research, 1997, 25, 182-189.	1.0	26
45	Biliary interleukin-6 and tumor necrosis factor-alpha in patients undergoing endoscopic retrograde cholangiopancreatography. Digestive Diseases and Sciences, 1997, 42, 1290-1294.	2.3	47
46	The rumination syndrome: clinical and manometric profile, therapy, and long-term outcome. Digestive Diseases and Sciences, 1997, 42, 1866-1872.	2.3	64
47	Effect of octreotide on human sphincter of Oddi motility following liver transplantation. Digestive Diseases and Sciences, 1997, 42, 1168-1175.	2.3	6
48	The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Alimentary Pharmacology and Therapeutics, 1997, 11, 381-385.	3.7	27
49	Cosegregation of familial intestinal pseudoobstruction and presence of digital arches in a large multigenerational pedigree. Digestive Diseases and Sciences, 1996, 41, 1429-1433.	2.3	5
50	BILIARY TRACT COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION ENDOSCOPIC APPROACH TO DIAGNOSIS AND THERAPY. Transplantation, 1995, 60, 467-470.	1.0	104
51	Determining required stent length in endoscopic retrograde biliary stenting. Gastrointestinal Endoscopy, 1995, 41, 242-243.	1.0	6
52	Prophylactic Treatment Regimens for the Prevention of Hepatitis A. Drugs, 1991, 41, 883-888.	10.9	8